Categories
BLOG

etst cbd

Emerging Markets Report – Earth Sciences Tech Inc at the Forefront of the CBD Revolution

ORLANDO, Fla., Jan. 15, 2020 (GLOBE NEWSWIRE) — The early adoption of any new technology is always a tricky matter. In the case of most “tech”–namely, machines that offer new functionalities–the market always has the first and final say as to the true value of the product. But in the case of biotech, there’s an additional hurdle that lay ahead of the market mechanism: regulatory testing and approval.

Cannabinoid-based products, popularly referred to as “CBD,” comprise one such category. It’s most popular form of use and consumption as a nutraceutical (e.g. capsule and food forms), CBD products are currently in transition in the US, legal in most states, pending legalization in others. CBD exhibits every characteristic of a budding and promising industry. From an investment perspective, this presents a ground level opportunity for those who have the foresight, means, and (to be quite frank) courage to wager on an industry’s growth potential while still in its nascent phase.

An Emerging Company with a Formidable R&D and Executive Team
Earth Sciences Tech Inc (ETST) is one company jostling for space on the cutting edge of this new industry. When assessing a company in any emerging field, you’d have to look at the factors that may not only differentiate a company from its competitors, but that may also give that one company greater potential in an industry that’s still unformed, uncertain, and in some cases (as in CBD) partly unregulated.

First off, ETST is not a new entrant in the CBD market. Both ETST’s advisory board and executives come with serious scientific and business credentials that many small companies in the CBD space may find difficult to match.

Full Spectrum Products for a Wide Spectrum of Treatments
Although the term “CBD” is often used synonymously with several different types of cannabinoid products, it’s important to realize that there’s a technical distinction. CBD is one of 80 different phytocannabinoid components. Among the more popular derivatives are CBD, CBC, CBG, CBN CBDA, and CBDV–enough to confuse just about everyone besides the scientists who work closely with cannabinoids. Hence, “CBD” is often thrown around as a catch-all term.

But not all CBD products “catch all” of the components derived from the cannabis plant unless it is a “full spectrum” product. And ETST’s product line is full spectrum focused. Their products comprise a wide range, consisting of oils and capsules, their applications encompassing medical to mental health treatments. They even have a dedicated line of products designed for pets (yes, cats and dogs).

For investors, perhaps one of the more exciting aspects of CBD is its applications toward research, particularly instances where such applications may constitute breakthroughs in the medical field. For instance, the University of Central Oklahoma has seen positive results in studies concerning the administration of ETST’s high-grade full spectrum CBD beverages (to which the University shares a provisional patent) in cases of breast cancer and immune cells.

ETST has been developing, manufacturing, and distributing these beverages for public consumption. The company estimates that this product alone can potentially yield $11.7 billion in the coming year, and grow into a $25 billion market within seven years–a prospect that ETST aims to capture, leveraging its medically-tested results as a means to drive product line revenue.

According to ETST’s CEO and CSO, Michel Aube (as quoted in MarketWatch):

“The CBD beverage is a most in the…[inaudible]. poque of legalization of recreative marijuana. Not only does CBD have positive effects on immune cells, it has strong antioxidant and anti-psychotic properties. Indeed, it is now well recognized that CBD is an anti psychotic molecule and that CBD has opposite effect to -9-t…[inaudible]. tetrahydrocannabinol (THC). This is why health professions are concerned by the fact that most marijuana plants have very low concentration of CBD and huge amount of THC molecule. At Earth Science Tech we focused on full spectrum cannabinoids derived from industrial hemp that contains extremely low to no THC since THC is psychoactive causing dependency and mental illness in young individuals. This means that all our products are beneficial for recreational marijuana consumer because it helps them to balance their intake of psychoactive and antipsychotic cannabinoids. Our cannabinoid products help to counter the side effects of THC in addition of having itself other interesting biological activities like anti-inflammatory and antioxidant properties.”

In addition, all of the company’s products are “legal in all 50 states,” according to its website, giving it a timing advantage among its peers seeking regulatory approval.

Market Performance at a Low Point May Signal a Speculative Value Opportunity
With its highest high at $5.00 and its lowest low at the current level of $0.07, there’s no doubt that ETST is not an investment for the faint-hearted. You can’t just casually invest in a stock like this in the same manner that you might with other stocks for the sake of portfolio diversification.

Most people following the stock may be aware that one of ETST’s major shareholders, Group, Ltd. Majorca, had sold 129620 shares, according to SEC filings submitted on Oct 9. Very few details are available with regard to the reason behind the sale.

At this juncture, and like every investment in emerging technologies and industries, one would base the worthiness of investment not on current proof of profit but on profit potential.

About The Emerging Markets Report:

The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.

For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php

Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.

We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.

ORLANDO, Fla., Jan. 15, 2020 (GLOBE NEWSWIRE) — The early adoption of any new technology is always a tricky matter. In the case of most “tech”–namely,…

Earth Science Tech, Inc. (ETST) Issues Update on CBD Patents and Reacts to DEA’s Shift on CBD

DORAL, Florida, Oct. 03, 2018 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today provides an update on the progression of its cannabidiol (“CBD”) patents and reacts to the U.S. Drug Enforcement Agency’s (“DEA”) recent decision to remove certain CBD products from its Schedule 1 list of controlled substances.

As previously announced, ETST will soon launch its two CBD-based nutraceutical formulas – a neuron protector and a breast protector – under the provisory patent. In tandem, the Company is developing a new brand for these two formula patents.

ETST further announces that the Quebec Agrifood Innovation Center (“QAIC”) is finishing the standardization of the formulas. By the end of October, TransBiotech will conduct in vitro testing for the formulas’ biological activities, comparing the level of protection provide by ETST’s hemp oil alone versus its hemp oil with other natural ingredients. These components have been meticulously chosen for their bioactivity.

“The results obtained from TransBiotech will help us understand the mechanism of action of CBD and will open the doors for the research needed to develop revolutionary CDB-based pharmaceutical drugs,” says ETST president and CEO Nickolas Tabraue. “We will provide more details on the progress of these formulas in the near future, as well as an update on the first CBD-based pharmaceutical product we are developing with Bionatus for the treatment of asthma, as announced last year.”

In addition to nutraceutical formulas, ETST’s pipeline also includes CBD-based pharmaceutical formulas. As legalization of cannabis and cannabis-based products continues to spread, ETST expects that its pure hemp oil and new formulas will eventually be sold worldwide. As announced previously, ETST will be a licensed distributor and will work closely with pharmacists and researchers to serve the burgeoning cannabis market.

This expectation is emboldened by the DEA’s recent decision to reclassify FDA-approved drugs that contain cannabis-derived CBD and less than 0.1% tetrahydrocannabinol (THC) as schedule V, the lowest restriction classification. The decision follows the FDA’s first approval of a non-synthetic CBD-based drug to treat rare types of epilepsy.

Once the ruling goes into effect, it could open the door for companies like ETST to develop treatments for other illnesses. The new classification will also render clinical studies with CBD easier to plan.

ETST CEO and Chief Science Officer Dr. Michel Aubé is ecstatic about the changes. “In 2018, we have a much deeper understanding of cannabinoids, cannabinoid-receptors, and the endocannabinoid system than we did decades ago when CBD was classified as a schedule 1 drug. We are pleased to see that the DEA has shifted its stance amid conclusive evidence that CBD is not addictive but has both anti-psychotic properties and the opposite effect of THC.”

ETST plans to share further updates on its CBD patent formulas and CBD-based pharmaceuticals as each progress.

About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.

ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors::

Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical (“ESP”) is a wholly owned subsidiary of Earth Science Tech), committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com

Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly owned subsidiary of Earth Science TechTich i poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com

KannaBidioiD, Inc.
KannaBidioiD (“KBD”) is a wholly owned subsidiary of Earth Science TechB that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com

Earth Science Foundation, Inc.
Earth Science Foundation. (“ESF”) is a wholly owned subsidiary of Earth Science Tech. ESF is in the process of becoming a nonprofit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech’s effective CBD products to those in need. To learn more please visit: www.ETSTFoundation.org

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

DORAL, Florida, Oct. 03, 2018 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused…